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ABSTRACT
Infection with hepatitis C virus (HCV) is a global public health issue. The bloodborne 
nature of HCV transmission poses a substantial risk to healthcare workers, due 
to occupational exposure to needlestick injuries and blood and other body fluids 
containing the virus. Undiagnosed HCV infection, including in healthcare workers, 
represents a growing problem worldwide as the infected population ages, and 
HCV-related mortality and morbidity is expected to rise substantially over the 
coming decades. Consequently, diagnostic tests for HCV play an important role 
in this scenario. The aim of this study was to standardize a one-step RT-PCR 
assay for detection of HCV. The test demonstrated reproducibility, sensibility 
(100%), and the limit of detection was set at 100IU/mL. Our study indicates that 
this assay can be used as a diagnostic tool to follow up healthcare workers after 
occupational exposure. 
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Infection with hepatitis C virus (HCV) is a global public health issue. More 
than 170 million persons worldwide are infected with HCV1. Furthermore, 
the bloodborne nature of HCV transmission poses a substantial risk to 
healthcare workers, due to occupational exposure to needlestick injuries 
and blood, and other body fluids containing the virus2,3. Undiagnosed HCV 
infection, including in healthcare workers, represents a growing problem 
worldwide as the infected population ages, and HCV-related mortality 
and morbidity is expected to rise substantially over the coming decades4. 
Consequently, diagnostic tests for HCV play an important role in this 
scenario. Molecular assays (nucleic acid tests, NATs) are considered the 
gold standard for diagnosis of HCV infection5. In many countries, these 
tests are part of routine screening programmes, as they allow detection of 
infection before the immune response, which is the target of serological 
testing6,7. Furthermore, qualitative NATs are used to confirm viremia, which 
aids in the diagnosis of acute HCV infection8. Thus, qualitative HCV NATs 
play an extremely important role in the follow-up of occupational exposures 
to blood. In occupational exposures, as in acute infections, NAT results 
will become positive within 1 to 3 weeks — several weeks earlier than any 
serological test8.
Real-time PCR (RT-PCR) is one of the most recent NAT assays for 
diagnosis of HCV RNA9. Several NATs have used the 5´NCR region of the 
HCV genome as a target for primers and probes10. As a highly conserved 
region, this is the target of choice for many in-house and commercial tests. 
However, there is disagreement as to the performance of the 5´NCR region 
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as a target in different HCV genotypes11. Recent 
studies have proposed the use of a new target 
region of the HCV genome, an additional element 
adjacent to the poly (U) tract of the 3´UTR known 
as the 3´-X-tail, or simply the X tail. This region is 
also highly conserved, and is believed to enable 
detection of all HCV genotypes12,13.
The aim of this study was to standardize a 
qualitative NAT assay, specifically a one-step 
RT-PCR assay targeting the X-tail region of the 
HCV genome, for use as a diagnostic test for 
acute HCV infection.
METHODS
The one-step RT-PCR assay was run on 30 
human plasma samples previously evaluated by 
means of a HCV NAT test (COBAS Amplicor HCV 
system Assay 2.0, Roche). Fifteen samples were 
positive and 15 were negative. The positive samples 
were sequenced for detection of the HCV genotype 
(1, 2, and 3). All plasma specimens used in the study 
were obtained from the collection of the “Centro de 
Desenvolvimento Científico e Tecnológico - Fundação 
Estadual de Produção e Pesquisa em Saúde”, Porto 
Alegre, state of Rio Grande do Sul, Brazil. Specimens 
were stored at -80°C until use.
RNA was extracted with a QIAamp Mini Kit 
(Qiagen, Valencia, CA, USA) using 500 µL of 
plasma, 11.2 µg/ sample of carrier RNA, and 
30 µL of elution buffer. Modifications in the 
sample volume, in carrier RNA quantity, and 
elution buffer volume were introduced in the 
QIAamp Mini Kit manufacturer’s protocol to 
improve the sensitivity of RNA extraction. Primers 
(XTF5 – 5’GTGGCTCCATCTTAGCCCTAGT3’ and 
HCMgR2 – 5’TGCGGCTCACGGACCTTT3’ at 
400 nM by Invitrogen, Carlsbad, CA, USA) and 
probe (HCVMGB2 5’FAM- CACGGCTAGCTGTG-
MGB3’ at 200 nM by Applied Biosystems, Foster 
City, CA, USA) were used to amplify the X-tail 
region as described by Drexler et al. The reaction 
was performed using a SuperScriptTM III Platinumâ 
One-Step Quantitative RT-PCR System (Invitrogen, 
Carlsbad, CA, USA) containing 6 mM of MgCl. 
Detection of a human gene (RNase P) was 
incorporated as the internal control. Thermal cycling 
was performed in a 7500 Real Time PCR System 
(Applied Biosystems, Foster City, CA, USA) as 
follows: 50°C for 30 min, 95°C for 2 min, 45 cycles 
at 94°C for 15 s, and 55°C for 35 s.
To evaluate the test reproducibility and LOD of 
our assay, we performed six runs of a commercial 
panel of HCV RNA samples (HCV RNA Linearity 
Panel PHW804 by BBI Diagnostics - SeraCare 
Life Sciences, Gaithersburg, MD, USA). This 
panel comprises 10 samples (PHW01 to 
PHW10) of HCV genotype 1. The HCV load of 
these samples had been quantified previously by 
three different techniques (Cobas Amplicor HCV 
Monitor V.2.0 - Roche; Versant HCV RNA bDNA 
3.0 - Bayer; HCV RNA Reference Lab Home 
Brew Real Time PCR). 
We performed serial dilutions of the PHW04 
sample followed by one-step RT-PCR to evaluate 
the limit of detection of the assay. These were 
tested in 16 replicates for determination of the LOD.
RESULTS
The one-step RT-PCR technique described 
herein proved to be reproducible across the six 
replicates of each PHW sample (1 to 10), as the 
%CV obtained for each positive panel member 
was 3.39% for PHW1, 2.08% for PHW2, 2.94% 
for PHW3, 1.91% for PHW4, and 2.07 for PHW5. 
There was satisfactory linearity as tested with the 
HCV RNA Linearity Panel – PHW804 (Figure 1). 
The PHW04 sample (20000 IU/mL) was diluted 
serially to obtain HCV concentrations of 1000 IU/mL, 
500 IU/mL, 200 IU/mL, 100 IU/mL, 50 IU/mL, and 
10 IU/mL. One-step RT-PCR was consistently 
able to detect all 16 replicates of each tested 
concentration up to 100 IU/mL. 
All 30 clinical samples previously evaluated in 
the COBAS Amplicor HCV exhibited the same result 
on one-step RT-PCR, whether positive or negative. 
In fact, all three genotypes presented positive results, 
indicating that the X-tail region is an adequate target 
for HCV detection (Table 1). 
CT: Cycle Threshold
Figure 1: Reproducibility and linearity of the panel sample 
across six repetitions of each sample (1 to 10). 
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DISCUSSION
The aim of this study was to standardize a one-
step RT-PCR assay to the X-tail region of HCV as a 
qualitative NAT for use in the setting of acute infection. 
This is a highly relevant issue in health care facilities, as 
many protocols for follow-up of occupational exposure 
to HCV require NATs with good specificity and 
sensitivity. In the acute infection period, most patients 
develop asymptomatic infection but will often have 
high-level viremia and high alanine aminotransferase 
(ALT) levels. HCV RNA can be detected 1 to 3 weeks 
after infection, approximately 1 month earlier than 
anti-HCV antibodies8. Furthermore, direct detection 
of HCV RNA has become an essential tool for the 
diagnosis of hepatitis C acute infection. 
In this study, the one-step RT-PCR assay using 
the X-tail region of HCV as a target was able to 
detect all samples previously confirmed as positive 
by means of the COBAS Amplicor HCV test. 
Notably, all HCV genotypes (1, 2, and 3) were 
detected equally by both techniques. As these 
genotypes (1 to 3) are the most prevalent in 
Brazil15,16. RT-PCR exhibited high sensitivity and, 
therefore, is adequate for use as a diagnostic test 
in our country. This test also proved to be highly 
specific, as none of the 15 previously negative 
samples tested positive.
In addition, this assay incorporates RNAse P gene 
amplification as an internal control. A positive RNAse 
P reaction ensures that the quality of the sample is 
acceptable, and the internal-control is positive while 
target-negative reactions ensure a true negative 
result. Furthermore, RNAse P amplification performed 
as a separate reaction has shown better performance 
than the internal controls used by commercial assays. 
The use of RNAse P could thus reduce the costs and 
turnaround time of HCV NAT.
Table 1: Results of COBAS Amplicor HCV system Assay 2.0 – Roche and the one-step Real Time PCR HCV assay.
Sample Genotype COBAS Amplicor test Cobas Internal Control RT-PCR in house Internal Control
160 2 + - +     (CT 32.9) +     (CT 33.8)
177 3 + + +     (CT 37.1) +     (CT 32.9)
157 1 + + +     (CT 32.2) +     (CT 34.3)
168 3 + + +     (CT 32.4) +     (CT 34.9)
153 1 + + +     (CT 28.9) +     (CT 35.7)
139 3 + - +     (CT 30.9) +     (CT 34.1)
159 1 + + +     (CT 33.2) +     (CT 35.3)
162 2 + + +     (CT 31.5) +     (CT 34.7)
109 3 + + +     (CT 36.4) +     (CT 34.6)
164 1 + + +     (CT 32.7) +     (CT 32.7)
143 3 + - +     (CT 30.4) +     (CT 32.7)
142 2 + - +     (CT 34.7) +     (CT 32.2)
174 3 + + +     (CT 26.1) +     (CT 33.0)
171 3 + + +     (CT 30.5) +     (CT 33.7)
146 3 + + +     (CT 36.0) +     (CT 33.6)
110 - - + - +     (CT 33.7)
97 - - + - +     (CT 33.9)
120 - - + - +     (CT 35.0)
123 - - + - +     (CT 35.6)
122 - - + - +    (CT 35.8)
115 - - + - +    (CT 35.4)
125 - - + - +     (CT 34.9)
128 - - + - +     (CT 36.7)
101 - - + - +     (CT 41.0)
108 - - + - +     (CT 35.1)
97 - - + - +     (CT 34.3)
124 - - + - +     (CT 32.7)
95 - - + - +     (CT 34.9)
120 - - + - +     (CT 34.9)
99 - - + - +     (CT 35.1)
CT: Cycle Threshold.
X-tail target of HCV as diagnostic test 
http://seer.ufrgs.br/hcpa Clin Biomed Res 2014;34(2) 167
The LOD was established as 100 IU/mL, which 
is similar to that of other in-house assays for 
PCR-based HCV detection5,17. Many commercial 
assays report a LOD of 50 IU/mL. However, our 
one-step RT-PCR assay was designed for patient 
monitoring in the acute setting; this HCV NAT will 
be applied mainly in protocols for follow-up of 
health care workers after occupational exposure. 
In this period of HCV infection, patients exhibit 
high-level viremia8,18, and a nucleic acid test with 
a LOD of 100 IU/mL is acceptable.
Our findings suggest that the one-step RT-PCR 
assay proposed herein is reproducible, specific, 
and sensitive for use as a HCV NAT in the acute 
setting. Therefore, this assay can be used as a 
diagnostic tool to follow up health care workers 
after occupational exposure.
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